| Database ID | Agent | Target | Cancer Type | Detail |
| DB00991 | cetuximab | Epidermal growth factor receptor | colorectal cancer | view |
| DB00992 | bevacizumab | Vascular endothelial growth factor | colorectal cancer | view |
| DB00993 | panitumumab | Epidermal growth factor receptor | colorectal cancer | view |
| DB00994 | bevacizumab | Vascular endothelial growth factor | colorectal cancer | view |
| DB00995 | trebananib | Angiopoietin2, Angiopoietin1 | colorectal cancer | view |
| DB00996 | Dalotuzumab Cetuximab | NA | colorectal cancer | view |
| DB00997 | cediranib | Vascular endothelial growth factor receptor 2 | biliary tract and gallbladder cancer | view |
| DB00998 | bevacizumab | Vascular endothelial growth factor | colorectal cancer | view |
| DB00999 | cetuximab | Epidermal growth factor receptor | colorectal cancer | view |
| DB01000 | afatinib | Receptor proteintyrosine kinase erbB2
Epidermal growth factor receptor | non small cell lung cancer | view |
| DB01001 | necitumumab | Epidermal growth factor receptor | non small cell lung cancer | view |
| DB01002 | gefitinib | Epidermal growth factor receptor | non small cell lung cancer | view |
| DB01003 | dacomitinib | Epidermal growth factor receptor, Proto oncogene proteinc mdm2, Erbb2 tyrosine kinase receptor | non small cell lung cancer | view |
| DB01004 | ramucirumab | Vascular endothelial growth factor receptor 2 | non small cell lung cancer | view |
| DB01005 | figitumumab | Insulinlike growth factor I receptor | non small cell lung cancer | view |